Cargando…
Current management approach to hidradenocarcinoma: a comprehensive review of the literature
Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612/ https://www.ncbi.nlm.nih.gov/pubmed/25815059 http://dx.doi.org/10.3332/ecancer.2015.517 |
_version_ | 1782362901434073088 |
---|---|
author | Soni, Abhishek Bansal, Nupur Kaushal, Vivek Chauhan, Ashok Kr |
author_facet | Soni, Abhishek Bansal, Nupur Kaushal, Vivek Chauhan, Ashok Kr |
author_sort | Soni, Abhishek |
collection | PubMed |
description | Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials. |
format | Online Article Text |
id | pubmed-4370612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-43706122015-03-26 Current management approach to hidradenocarcinoma: a comprehensive review of the literature Soni, Abhishek Bansal, Nupur Kaushal, Vivek Chauhan, Ashok Kr Ecancermedicalscience Review Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials. Cancer Intelligence 2015-03-19 /pmc/articles/PMC4370612/ /pubmed/25815059 http://dx.doi.org/10.3332/ecancer.2015.517 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Soni, Abhishek Bansal, Nupur Kaushal, Vivek Chauhan, Ashok Kr Current management approach to hidradenocarcinoma: a comprehensive review of the literature |
title | Current management approach to hidradenocarcinoma: a comprehensive review of the literature |
title_full | Current management approach to hidradenocarcinoma: a comprehensive review of the literature |
title_fullStr | Current management approach to hidradenocarcinoma: a comprehensive review of the literature |
title_full_unstemmed | Current management approach to hidradenocarcinoma: a comprehensive review of the literature |
title_short | Current management approach to hidradenocarcinoma: a comprehensive review of the literature |
title_sort | current management approach to hidradenocarcinoma: a comprehensive review of the literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612/ https://www.ncbi.nlm.nih.gov/pubmed/25815059 http://dx.doi.org/10.3332/ecancer.2015.517 |
work_keys_str_mv | AT soniabhishek currentmanagementapproachtohidradenocarcinomaacomprehensivereviewoftheliterature AT bansalnupur currentmanagementapproachtohidradenocarcinomaacomprehensivereviewoftheliterature AT kaushalvivek currentmanagementapproachtohidradenocarcinomaacomprehensivereviewoftheliterature AT chauhanashokkr currentmanagementapproachtohidradenocarcinomaacomprehensivereviewoftheliterature |